CoChat

The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification

Open access
Sauter, Jennifer L., Dacic, Sanja, Galateau-Salle, Francoise, Attanoos, Richard L., Butnor, Kelly J., Churg, Andrew, Husain, Aliya N., Kadota, Kyuichi, Khoor, Andras, Nicholson, Andrew G., Roggli, Victor, Schmitt, Fernando, Tsao, Ming-Sound, Travis, William D. · 2022 · Journal of Thoracic Oncology
Cited by 199

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Significant changes in the 2021 World Health Organization (WHO) Classification of Tumors of the Pleura and Pericardium since the 2015 WHO Classification include: 1) Pleural and pericardial tumors have been combined in one chapter whereas in the 2015 WHO, pericardial tumors were classified with cardiac tumors; 2) Well-differentiated papillary mesothelioma (WDPM) has been renamed well-differentiated papillary mesothelial tumor (WDPMT) given growing evidence that these tumors exhibit relatively indolent behavior; 3) Localized and diffuse mesothelioma no longer include the term "malignant" as a prefix; 4) Mesothelioma in situ (MIS) has been added to the 2021 classification since these lesions can now be recognized by loss of BAP1 and/or MTAP by immunohistochemistry and/or CDKN2A homozygous deletion by FISH; 5) The three main histologic subtypes (i.e. epithelioid, biphasic and sarcomatoid) remain the same but architectural patterns, cytologic and stromal features are more formally incorporated into the 2021 classification based on their prognostic significance; 6) Nuclear grading for epithelioid diffuse mesothelioma is introduced and it is recommended to record this and other histologically prognostic features in pathology reports; 7) BAP1, EZH2 and MTAP immunohistochemistry have been shown to be useful in separating benign mesothelial proliferations from mesothelioma; 8) Biphasic mesothelioma can be diagnosed in small biopsies showing both epithelioid and sarcomatoid components even if the amount of one component is less than 10%; and 9) The most frequently altered genes in diffuse pleural mesothelioma include BAP 1, CDKN2A, NF2, TP53, SETD2 and SETB1.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2021.12.014

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Metadata

Authors
Sauter, J. L., Dacic, S., Galateau-Salle, F., Attanoos, R. L., Butnor, K. J., Churg, A., Husain, A. N., Kadota, K., Khoor, A., Nicholson, A. G., Roggli, V., Schmitt, F., Tsao, M.-S., & Travis, W. D.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2022-05
Volume
17
Issue
5
Pages
608-622
ISSN
1556-0864 (ISSN-L)
OpenAlex
W4206195485
Cited by
199
References
7
FWCI
22.83
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. https://app.cochat.ai/papers/10.1016/j.jtho.2021.12.014
The paper
Sauter, J. L., Dacic, S., Galateau-Salle, F., Attanoos, R. L., Butnor, K. J., Churg, A., Husain, A. N., Kadota, K., Khoor, A., Nicholson, A. G., Roggli, V., Schmitt, F., Tsao, M.-S., & Travis, W. D. (2022). The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2021.12.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.